Scribe Therapeutics Inc. Common Stock

SCTX

Biotech & pharmaceuticalsEnergy & utilities

$21.17vs prev close▲+1.94(+10.09%)

$13.5052W Range$39.60

29% from low

-10.04 (-33.76%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

9 buys

Consecutive buys

1M net buy

+$10.3M

≈ +417K shares

Portfolio Weight

0.08%

1M -0.01%p

Holding ETFs

1 ETFs

ARKG

Price Effect (Buy)

Shares increased, but price decline reduced portfolio weight.

Shares +99.8% · Market value +5.1% · Weight -0.01%p

Trade Intensity

Concentrated buys

Basis: 0 sells · 9 buys in 1M

Trade Log9-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.08	BUY	ARKG	2,483	$19.23	$47.7K
26.10.07	BUY	ARKG	14,429	$17.57	$253.5K
26.10.06	BUY	ARKG	19,283	$16.33	$314.9K
26.10.05	BUY	ARKG	47,428	$16.21	$768.8K
26.09.24	BUY	ARKG	39,149	$21.61	$846.0K
26.09.23	BUY	ARKG	143,257	$26.53	$3.8M
26.09.22	BUY	ARKG	88,323	$28.07	$2.5M
26.09.21	BUY	ARKG	61,858	$28.05	$1.7M
26.09.16	BUY	ARKG	293	$29.10	$8.5K
26.09.08	BUY	ARKG	10,956	$31.34	$343.4K
26.08.31	BUY	ARKG	10,742	$30.54	$328.1K
26.08.28	BUY	ARKG	191	$28.44	$5.4K
26.08.27	BUY	ARKG	5,085	$28.84	$146.7K
26.08.18	BUY	ARKG	5,614	$27.11	$152.2K
26.08.17	BUY	ARKG	15,823	$21.19	$335.3K

10.08BUY

2,483

ARKGClose$19.23Est. total$47.7K

10.07BUY

14,429

ARKGClose$17.57Est. total$253.5K

10.06BUY

19,283

ARKGClose$16.33Est. total$314.9K

10.05BUY

47,428

ARKGClose$16.21Est. total$768.8K

09.24BUY

39,149

ARKGClose$21.61Est. total$846.0K

09.23BUY

143,257

ARKGClose$26.53Est. total$3.8M

09.22BUY

88,323

ARKGClose$28.07Est. total$2.5M

09.21BUY

61,858

ARKGClose$28.05Est. total$1.7M

09.16BUY

293

ARKGClose$29.10Est. total$8.5K

09.08BUY

10,956

ARKGClose$31.34Est. total$343.4K

08.31BUY

10,742

ARKGClose$30.54Est. total$328.1K

08.28BUY

191

ARKGClose$28.44Est. total$5.4K

08.27BUY

5,085

ARKGClose$28.84Est. total$146.7K

08.18BUY

5,614

ARKGClose$27.11Est. total$152.2K

08.17BUY

15,823

ARKGClose$21.19Est. total$335.3K

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

818,830

Portfolio Weight

0.08%

in ETF 0.54%

Est. Value

$13M

30D Net

+$11M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

None

Buy

Analyst Targets

avg.

$57.00

vs Current ▲ +169.2% upside

Current$21.17

Low ~ High$50.00 ~ $60.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

HC Wainwright & Co.

Buy

$60.00

+183.42%

—

Maintain

2026-09-03

HC Wainwright & Co.

Buy

$60.00

+183.42%

—

Upgrade

2026-08-31

Wells Fargo

Overweight

$60.00

+183.42%

—

Upgrade

2026-08-18

Leerink Partners

Outperform

$37.00

+74.78%

—

Upgrade

2026-08-18

Guggenheim

Buy

$50.00

+136.18%

—

Upgrade

2026-08-18

1 / 1

Avg Target

$57.00

vs Current ▲ +169.2% upside

None

4 analysts

Buy 4

Low $50.00

Current $21.17

High $60.00

Firm	Position	Target	Upside	Close	Action	Date
HC Wainwright & Co.	Buy	$60.00	+183.42%	—	Maintain	26.09.03
HC Wainwright & Co.	Buy	$60.00	+183.42%	—	Upgrade	26.08.31
Wells Fargo	Overweight	$60.00	+183.42%	—	Upgrade	26.08.18
Leerink Partners	Outperform	$37.00	+74.78%	—	Upgrade	26.08.18
Guggenheim	Buy	$50.00	+136.18%	—	Upgrade	26.08.18

1 / 1

Price Information

Previous Close$19.23

Open$19.18

Day Range$19.18 - $21.33

52-Week Range$13.50 - $39.60

1-Year Change11.60%

Trading Volume

Volume394,901

Avg Volume (3mo)358,120

Valuation

Market Cap400.8M

Book Value$-66.33

Shares Outstanding18,931,680

Financials

Revenue (TTM)33.3M

Net Income-32,304,000

EPS$-3.84

EBITDA-27,820,000

Profitability

P/E Ratio-

P/B Ratio-0.32

Return on Equity (ROE)-

Return on Assets (ROA)-

Profit Margin-97.00%

EV/EBITDA-18.74

Beta-

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)33.09

Company Overview

Scribe Therapeutics is a biotechnology company that develops CRISPR-based genetic medicines to treat the root causes of diseases, focusing on cardiometabolic conditions. Its main programs include STX-1150 for epigenetic silencing of the PCSK9 gene, STX-1200 for gene editing to lower Lp(a), and STX-1400 to target the APOC3 gene. The company uses platforms like ELXR and XE to enable precise gene editing and silencing, and it operates as a clinical-stage firm based in Alameda, California.

P/B

-0.32

Negative equity

ROE

Return on Equity

Beta

Market Volatility

RSI(14)

33.1

Neutral zone

AI-generated summary. Not investment advice.

Scribe Therapeutics Inc. Common Stock

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks